| Ulcerative Colitis
Inflectra vs Simponi
Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.Deep comparison between: Inflectra vs Simponi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSimponi has a higher rate of injection site reactions vs Inflectra based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Simponi but not Inflectra, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Inflectra
Simponi
At A Glance
IV infusion
Every 6-8 weeks
TNF-alpha antagonist
SC injection
Every 4 weeks
TNF-alpha inhibitor
Indications
- Ulcerative Colitis
- Rheumatoid Arthritis
- Ankylosing spondylitis
- Arthritis, Psoriatic
- Psoriasis vulgaris
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Ulcerative Colitis
Dosing
Crohn's Disease, Ulcerative Colitis 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks; regimen applies to adult and pediatric patients >= 6 years.
Rheumatoid Arthritis 3 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks in combination with methotrexate; may increase up to 10 mg/kg every 8 weeks or as often as every 4 weeks for incomplete response.
Ankylosing spondylitis 5 mg/kg IV at 0, 2, and 6 weeks, then every 6 weeks.
Arthritis, Psoriatic, Psoriasis vulgaris 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks.
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 50 mg SC once a month.
Ulcerative Colitis (adults and pediatric patients >=40 kg) 200 mg SC at Week 0, 100 mg at Week 2, then 100 mg every 4 weeks.
Ulcerative Colitis (pediatric patients >=15 kg to <40 kg) 100 mg SC at Week 0, 50 mg at Week 2, then 50 mg every 4 weeks.
Contraindications
- Doses >5 mg/kg in patients with moderate or severe heart failure
- Previous severe hypersensitivity reaction to infliximab products, inactive ingredients of INFLECTRA, or any murine proteins (including anaphylaxis, hypotension, and serum sickness)
—
Adverse Reactions
Most common (>10%) Infections (upper respiratory tract infection, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain
Serious Serious infections (pneumonia, cellulitis, abscess, sepsis, tuberculosis, opportunistic infections), malignancies, lymphoma, hepatotoxicity (acute liver failure, autoimmune hepatitis), severe infusion reactions, lupus-like syndrome
Postmarketing Agranulocytosis, neutropenia, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, peripheral demyelinating disorders (Guillain-Barre syndrome), acute liver failure, anaphylactic shock, cerebrovascular accidents, leukemia, melanoma, Merkel cell carcinoma
Most common (>=1%) Upper respiratory tract infection, viral infections, bronchitis, superficial fungal infections, sinusitis, injection site reaction, alanine aminotransferase increased, aspartate aminotransferase increased, hypertension, dizziness, paresthesia, constipation
Serious Serious infections, malignancies, congestive heart failure, demyelinating disorders, hepatitis B reactivation, autoimmunity, hematologic cytopenias, hypersensitivity reactions
Postmarketing Serious systemic hypersensitivity reactions, sarcoidosis, melanoma, Merkel cell carcinoma, interstitial lung disease, skin exfoliation, lichenoid reactions, rash, bullous skin reactions
Pharmacology
Infliximab-dyyb is a chimeric IgG1kappa monoclonal antibody TNF-alpha antagonist that neutralizes the biological activity of TNFalpha by binding with high affinity to soluble and transmembrane forms of TNFalpha, inhibiting receptor binding and downstream proinflammatory cytokine activity in RA, CD, UC, AS, PsA, and Ps.
Golimumab is a human IgG1 monoclonal antibody (TNF-alpha inhibitor) that binds to both the soluble and transmembrane bioactive forms of human TNF-alpha, preventing its binding to receptors and inhibiting the biological activity of TNF-alpha in inflammatory diseases.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Inflectra
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Simponi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Inflectra
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Simponi
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (7/8) · Qty limit (7/8)
Humana
Inflectra
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Simponi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Inflectra Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Simponi.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
InflectraView full Inflectra profile
SimponiView full Simponi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.